Business Context and Reporting Period
This Form 8-K filing by Tempest Therapeutics, Inc. (TPST) reports a material event regarding its continued listing status on The Nasdaq Stock Market LLC. The report date is December 27, 2024, with the earliest event reported on the same date.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the trading price of the Company's common stock, which has closed below $1.00 per share for the last 30 consecutive business days.
Material Changes
The primary material change is the receipt of a notification from Nasdaq indicating a failure to satisfy the minimum closing bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). This deficiency has persisted for 30 consecutive business days as of the report date.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has 180 calendar days, until June 25, 2025, to regain compliance. To do so, the stock must close at or above $1.00 per share for 10 consecutive business days before the compliance date.
- Delisting Risk: If compliance is not achieved by the deadline, the Company may face delisting unless it qualifies for an additional 180-day period by meeting other listing standards and effecting a reverse stock split.
- Reverse Stock Split Authorization: On December 3, 2024, stockholders approved amendments to the Restated Certificate of Incorporation allowing the Board to effect a reverse stock split at a ratio between 1-for-2 and 1-for-15.
- Management Action: Management intends to actively monitor the stock price and evaluate options, including a potential reverse stock split, to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of TPST common stock to assess proximity to the $1.00 threshold.
- Monitor Board announcements regarding the specific ratio and timing of a potential reverse stock split.
- Review the Company's cash position in other filings (e.g., 10-K or 10-Q) to determine if liquidity constraints are driving the low stock price.
- Confirm the status of the Company's other Nasdaq listing requirements (e.g., market value of publicly held shares) to ensure eligibility for a second compliance period if needed.